https://www.copyright link/rear-window/bruce-mathieson-still-plugging-away-at-respiri-20210527-p57vpc
Despite attempting to commercialise its “wheeze test” for asthma for more than 10 years, it has yet to commercialise a product and reported the grand sum of $1000 in cash receipts for the three months to March 31. (Last March it did receive clearance from the US regulator, the FDA, to market and sell its patented Wheezo app, so maybe revenue will pick up.)
Its management team has also had a takeover bid for rival digital health micro-cap business Adherium knocked back on the basis it’s opportunistic and offers Respiri shares, rather than cash.
We can hardly blame Adherium’s shareholders for wanting to be paid in cash.
https://www.copyright link/rear-window/bruce-mathieson-still-plugging-aw...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.861M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 50256 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.12pm 04/10/2024 (20 minute delay) ? |
| ADR (ASX) Chart |
Day chart unavailable